Monarch Medical Technologies
www.monarchmedtech.comMonarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities of treating patients with diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, impaired kidney function, residual insulin, and presence of steroids.
Read moreMonarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities of treating patients with diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, impaired kidney function, residual insulin, and presence of steroids.
Read moreCountry
State
North Carolina
City (Headquarters)
Charlotte
Industry
Employees
11-50
Founded
2003
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Vice President , Hospital Solutions
Email ****** @****.comPhone (***) ****-****Vice President Clinical Affairs
Email ****** @****.comPhone (***) ****-****Enterprise Vice President of Sales
Email ****** @****.comPhone (***) ****-****President
Email ****** @****.comPhone (***) ****-****
Technologies
(39)